Aktis Oncology, Inc. ($AKTS)
Filing Information
| Accession Number | 0001193125-26-010566 |
|---|---|
| Form Type | 4 |
| Filing Date | Jan 12, 2026 |
| Document Date | Jan 12, 2026 |
| Document | View SEC Filing |
Transactions
8
Total Shares
24,829,212
Total Value
$15,030,000.00
P&L
+8.3% (+$1,252,500.00)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Director | Common Stock | โ | Jan 12, 2026 | Conversion | 4,859,370 | โ | โ | 4,859,370 | Indirect | See Footnote | View Details | |
Director | Common Stock | โ | Jan 12, 2026 | Purchase | 812,455 | $18.00 | $14,624,190.00 | 5,671,825 | Indirect | See Footnote | View Details | |
Director | Common Stock | โ | Jan 12, 2026 | Conversion | 134,842 | โ | โ | 134,842 | Indirect | See Footnote | View Details | |
Director | Common Stock | โ | Jan 12, 2026 | Purchase | 22,545 | $18.00 | $405,810.00 | 157,387 | Indirect | See Footnote | View Details | |
Director | Series A Redeemable Convertible Preferred Stock | Derivative | Jan 12, 2026 | Conversion | 14,838,250 | $0.00 | $0.00 | 0 | Indirect | See Footnote | View Details | |
Director | Series A Redeemable Convertible Preferred Stock | Derivative | Jan 12, 2026 | Conversion | 411,750 | $0.00 | $0.00 | 0 | Indirect | See Footnote | View Details | |
Director | Series B Redeemable Convertible Preferred Stock | Derivative | Jan 12, 2026 | Conversion | 3,648,750 | $0.00 | $0.00 | 0 | Indirect | See Footnote | View Details | |
Director | Series B Redeemable Convertible Preferred Stock | Derivative | Jan 12, 2026 | Conversion | 101,250 | $0.00 | $0.00 | 0 | Indirect | See Footnote | View Details |